The acquisitions happened fast this year—suspiciously fast, perhaps. AbbVie paid up to $2.1 billion for Capstan Therapeutics in June. Two months later, Kite Pharma shelled out $350 million for Interius BioTherapeutics. Both companies were chasing the same elusive prize: a way to manufacture CAR-T cancer therapies inside patients' bodies, rather than in sterile facilities that cost hundreds of millions to build.
Now Jennifer Doudna, the CRISPR pioneer who shared the 2020 Nobel Prize in Chemistry, is making her own play in that race.
Azalea Therapeutics, the Berkeley biotech she co-founded, announced November 4 that it raised $65 million in Series A financing led by Third Rock Ventures. Add in a $17 million seed round quietly closed in 2023, and Doudna's latest venture has pulled in $82 million to prove that genome editing can happen where it matters most—in patients, not petri dishes.
The timing tells you something. When Big Pharma starts acquiring your competitors before they've dosed a single human, you're either onto something genuinely transformative or riding a spectacular wave of hype. With CAR-T therapies, the answer might be both.
The $400,000 Problem
Today's CAR-T treatments work, sometimes remarkably well. But they require extracting a patient's T cells, shipping them to a specialized facility, genetically reprogramming them over weeks, and infusing them back—all for a price tag that can exceed $400,000 per patient. The process is so complex that only a handful of facilities worldwide can do it at scale.
"No ex vivo manufacturing, no lymphodepletion, theoretically scalable," is how Azalea describes its alternative approach. That's the pitch, anyway. Whether it works in humans is another question entirely.
The company's technology centers on what it calls Enveloped Delivery Vehicles—membrane-derived particles that carry CRISPR-Cas9 machinery specifically to T cells circulating in the bloodstream. These EDVs work in tandem with a modified adeno-associated virus delivering genetic instructions. Together, the dual-vector system inserts new genes at precise locations in the T cell genome, particularly targeting the TRAC locus where the cell's own regulatory machinery takes over.
It's elegant in theory. In practice, Azalea has published proof-of-concept data in Nature Biotechnology (January 2024) showing the approach generates functional CAR-T cells in humanized mice. Co-founder Justin Eyquem, a researcher at UCSF and the Gladstone Institutes, built on his own 2017 Nature paper demonstrating that TRAC-targeted CAR insertions enhance tumor destruction.
But mice aren't patients, and in vivo isn't ex vivo. The field has learned that lesson before.
A Crowded Field, Aggressive Investors
Azalea isn't alone in this pursuit—far from it. Umoja Biopharma closed a $100 million Series C in January 2025 after signing a collaboration with AbbVie the year prior. AAVivo is engineering T cell-targeting viral capsids. Abintus Bio, backed by the Leukemia & Lymphoma Society and Takeda, is developing non-replicating vectors for in vivo CAR reprogramming.
The investor enthusiasm is striking. RA Capital Management, which joined Azalea's Series A, previously led Capstan's $175 million Series B—just months before AbbVie acquired Capstan. The firm clearly believes someone will crack the code, even if it's betting on multiple horses.
Third Rock's Andrea van Elsas and Mary Lynne Hedley now sit on Azalea's board. Hedley co-founded TESARO, the oncology company GSK acquired for $5.1 billion in 2019, which perhaps explains the confidence. Reed Jobs—son of Steve Jobs and representing Yosemite Ventures—joined as a board observer alongside Doudna herself.
That's a lot of firepower for a company that incorporated just 28 months ago and operates out of shared lab space at UC Berkeley's Bakar BioLabs.
The Clinic Awaits
CEO Jenny Hamilton, a former postdoctoral researcher in Doudna's lab, told Fierce Biotech the company expects to dose its first patient in 12 to 18 months. The lead program targets CD19, a protein found on B cells, for treating blood cancers and autoimmune diseases. A second effort goes after BCMA for multiple myeloma. A third program, focused on solid tumors, remains under wraps.
Hamilton received a $1 million award from the Innovative Genomics Institute in September 2023—part of the early academic de-risking that got Azalea off the ground. The company spun out from collaborative work between Doudna's Berkeley lab and Eyquem's UCSF group, with seed backing from Yosemite and the Parker Institute for Cancer Immunotherapy.
The company plans to present new data on in vivo TRAC CAR-T generation at the American Society of Gene & Cell Therapy's meeting on targeted gene editing, scheduled for November 20 in San Diego. Those results will offer a clearer picture of whether Azalea's approach can overcome the biological complexity of editing cells inside a living human.
For now, the $65 million will fund IND-enabling studies for the CD19 program, advance BCMA work toward clinical trials, and explore whether the platform can be adapted beyond T cells to other cell types—natural killer cells, perhaps, or macrophages.
A Pattern Emerges
Step back, and a pattern becomes visible. The field of in vivo cell therapy has moved from academic curiosity to investor obsession in less than three years. The wave of acquisitions suggests pharmaceutical giants recognize they can't build this technology in-house fast enough. Better to buy it early, even at eye-watering prices.
Azalea's advantage—if it has one beyond Doudna's name recognition—lies in its CRISPR foundation. The company can theoretically make precise, permanent edits rather than relying solely on viral integration, which sometimes lands genes in problematic genomic locations. That precision might matter less if the therapy doesn't work, of course.
The real test comes when Azalea doses its first patient. Ex vivo CAR-T manufacturing may be expensive and cumbersome, but it's a controlled environment where scientists can verify what they've built before it goes into a human. In vivo editing means trusting that your vectors find the right cells, insert genes correctly, and don't cause off-target effects—all while the immune system tries to clear your delivery vehicles from circulation.
It's a harder problem than it looks. Which is probably why two of Azalea's competitors have already opted for the certainty of an acquisition check over the uncertainty of clinical development.
For Doudna and her co-founders, the next 18 months will reveal whether their Nobel-winning technology can solve a problem that's vexed an entire industry. The science is promising. The capital is there. Now comes the part where biology gets a vote.
